BTOG 2022 | Assessing the value of immunotherapy in mesothelioma

Paul Baas, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the benefits of immunotherapy as the standard of care in mesothelioma, especially in non-epithelioid mesothelioma. Despite chemotherapy having slight optimal survival rates 4-6 months after treatment, immunotherapy can have greater benefit in certain patients based on immunological status and tumor size. Prof. Baas additionally highlights the use of tyrosine kinase inhibitors (TKI) with immunotherapy, and how further research is needed in developing therapies for epithelioid mesothelioma. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.